MARKET

INO

INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.49
-0.33
-3.74%
After Hours: 8.49 0 0.00% 19:43 06/18 EDT
OPEN
8.76
PREV CLOSE
8.82
HIGH
8.81
LOW
8.44
VOLUME
5.60M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
5.81
MARKET CAP
1.78B
P/E (TTM)
-7.5514
1D
5D
1M
3M
1Y
5Y
Will coronavirus eventually become like the seasonal flu?
Morsa Images/DigitalVision via Getty Images Gone are the days when epidemiologists poured over Covid-19 case numbers, as well as new infections and related deaths. As a broad vaccine rollout in
Seekingalpha · 4h ago
Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market
marketwatch.com · 1d ago
Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day
marketwatch.com · 2d ago
Is Inovio Stock A Buy After Inking A New Deal For Its Covid Vaccine?
Is INO stock a buy after expanding its partnership with Advaccine to run a Phase 3 test of its Covid vaccine? Inovio stock soared on the news.
Investor's Business Daily · 3d ago
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
marketwatch.com · 3d ago
Should You Buy Biotech ETFs Now?
Zacks.com · 4d ago
Inovio Pharmaceuticals Could Continue to Rally on Meme Stock Euphoria
The meme stock rally has taken off in recent weeks. Shares of everything from AMC Entertainment (AMC) to GameStop (GME) and BlackBerry (BB) have seen violent swings since late May. Investors in the most well-know meme stocks have certainly benefited from t...
TipRanks · 4d ago
Inovio Pharmaceuticals Inc. stock falls Tuesday, underperforms market
marketwatch.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 13.63 with a high estimate of 35.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 330
Institutional Holdings: 77.31M
% Owned: 36.92%
Shares Outstanding: 209.40M
TypeInstitutionsShares
Increased
85
10.66M
New
36
5.46M
Decreased
52
3.73M
Sold Out
47
3.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.57%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Non-Executive Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Non-Executive Vice Chairman/Independent Director
Jay Shepard
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Elizabeth Shea
Chief Operating Officer
Jacqueline Shea
Chief Scientific Officer
Laurent Humeau
Director
Roger Dansey
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
No Data
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.